Tag Archives: BMY

Week In Review: Nearly $2 Billion Late-December Week For China Pharma Deals

Nanjing Legend Biotech received a $350 million upfront payment from Janssen Biotech, which will form a global partnership with Legend for its highly effective CAR-T candidate. In June, Legend, which was not previously well known, surprised the annual ASCO meeting with stunningly positive results from an early trial of the CAR-T molecule in patients with multiple myeloma. In addition to the $350....More>>>

10 Biotech Stocks With Game-Changing Dates in Q3

For some investors, they’ve created small fortunes. For others, they’ve brought nothing but misery. For all investors, though, there’s no denying the fact that biotech stocks have kept things interesting if only because they can always supply a binary even traders can treat like a coin toss. The third quarter of 2017 isn’t going to be any different.


Should You Buy Gilead Sciences, Inc (GILD) Stock Ahead Of Q4 Earnings?


Shares of Foster City, California-based, biotech major, Gilead Sciences, Inc(NASDAQ:GILD) have been on a consistent decline in the last one year or so. After being one of the best performers in the biotech space since 2012, Gilead stock has lost more than 12% in last one year, while theNasdaq Composite (INDX:COMPX) has gained by more than 24% in the same period, resulting in....More>>>

Bristol-Myers Squibb: Much Ado About (Almost) Nothing

“Mors tua, vita mea” (literally “your death is my life) probably was the motto that gladiators, in the ancient Rome, recited before entering in the Coliseum and fighting for their life. Over and above its literal translation, this Latin expression means that what is a damage for one person is often an advantage for another. There can only be one winner in a competition;....More>>>

Bristol-Myers Squibb: There Goes Any Chance for Upside

Poor Bristol-Myers Squibb (BMY)–and poor anyone who had been bullish on its shares.

That would include Barron’s Jack Hough, who listed it as a stock on sale on Jan. 13. It’s even more on sale today, however, after Bristol-Myers said that it wouldn’t seek accelerated approval of its lung-cancer treatment combination last night, with shares off 10% at $49.94....More>>>

Bristol-Myers, Target Sink into Friday’s 52-Week Low Club

January 20, 2017: Here are four stockstrading with relatively heavy volume among 54 equities making new 52-week lows in Friday’s session. On the NYSE, advancers led decliners by nearly 2 to 1 and on the Nasdaq advancers led decliners by about 3 to 2.

Bristol-Myers Squibb Co. (NYSE: BMY) dropped about 11.8% Friday to post a new 52-week low of $48.92 after closing Thursday at....More>>>